{"schema_version":"secwatch.filing_event.v1","accession":"0001933414-24-000015","form_type":"8-K","ticker":"MLYS","cik":"0001933414","company_name":"Mineralys Therapeutics, Inc.","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:21.242145+00:00","generated_at":"2026-06-02T07:15:37.002202+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Mineralys Q1 net loss $31.5M; cash $338.6M; Advance-HTN topline due Q4 2024","bullets":["Net loss of $31.5M for Q1 2024, up from $12.6M in Q1 2023; R&D expenses $30.8M.","Cash, equivalents and investments $338.6M as of March 31, 2024; private placement net ~$116M in Q1.","Advance-HTN pivotal trial topline data expected in Q4 2024.","Launch-HTN Phase 3 trial topline data anticipated in 2H 2025.","Explore-CKD Phase 2 topline data expected Q4 2024 to Q1 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001933414-24-000015","json":"https://secwatch.observer/filing/0001933414-24-000015.json","markdown":"https://secwatch.observer/filing/0001933414-24-000015.md","text":"https://secwatch.observer/filing/0001933414-24-000015.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1933414/000193341424000015/0001933414-24-000015-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1933414/000193341424000015/mlys-20240509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T07:15:37.002202+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8b44af5ae6a8315c00c27900564c593a8eabf4a6","claim":"Mineralys Therapeutics, Inc. reported the quarter ended March 31, 2024 results: net income $31.5 million.","evidence_excerpt":"Net loss was $31.5 million for the quarter ended March 31, 2024, compared to $12.6 million for the quarter ended March 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1933414/000193341424000015/0001933414-24-000015-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2024"},{"label":"Net income","value":"$31.5 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}